UCB SA (UCB.BR) Stock Fundamental Analysis

EBR:UCB • BE0003739530

269.25 EUR
-1.65 (-0.61%)
Last: Feb 25, 2026, 11:39 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

6

Taking everything into account, UCB scores 6 out of 10 in our fundamental rating. UCB was compared to 52 industry peers in the Pharmaceuticals industry. UCB has an excellent financial health rating, but there are some minor concerns on its profitability. UCB shows excellent growth, but is valued quite expensive already. These ratings would make UCB suitable for growth investing!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • UCB had positive earnings in the past year.
  • In the past year UCB had a positive cash flow from operations.
  • UCB had positive earnings in each of the past 5 years.
  • Each year in the past 5 years UCB had a positive operating cash flow.
UCB.BR Yearly Net Income VS EBIT VS OCF VS FCFUCB.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

1.2 Ratios

  • UCB has a Return On Assets of 7.75%. This is comparable to the rest of the industry: UCB outperforms 55.77% of its industry peers.
  • UCB has a Return On Equity (13.76%) which is in line with its industry peers.
  • With a Return On Invested Capital value of 11.63%, UCB perfoms like the industry average, outperforming 57.69% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for UCB is significantly below the industry average of 14.12%.
  • The 3 year average ROIC (4.35%) for UCB is below the current ROIC(11.63%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 7.75%
ROE 13.76%
ROIC 11.63%
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
UCB.BR Yearly ROA, ROE, ROICUCB.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2 4 6 8 10

1.3 Margins

  • The Profit Margin of UCB (19.45%) is better than 73.08% of its industry peers.
  • UCB's Profit Margin has been stable in the last couple of years.
  • UCB's Operating Margin of 26.58% is fine compared to the rest of the industry. UCB outperforms 65.38% of its industry peers.
  • UCB's Operating Margin has declined in the last couple of years.
  • The Gross Margin of UCB (73.38%) is better than 63.46% of its industry peers.
  • In the last couple of years the Gross Margin of UCB has remained more or less at the same level.
Industry RankSector Rank
OM 26.58%
PM (TTM) 19.45%
GM 73.38%
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
UCB.BR Yearly Profit, Operating, Gross MarginsUCB.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • UCB has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • UCB has about the same amout of shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, UCB has more shares outstanding
  • UCB has a better debt/assets ratio than last year.
UCB.BR Yearly Shares OutstandingUCB.BR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
UCB.BR Yearly Total Debt VS Total AssetsUCB.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

  • UCB has an Altman-Z score of 5.66. This indicates that UCB is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 5.66, UCB belongs to the top of the industry, outperforming 82.69% of the companies in the same industry.
  • UCB has a debt to FCF ratio of 2.43. This is a good value and a sign of high solvency as UCB would need 2.43 years to pay back of all of its debts.
  • The Debt to FCF ratio of UCB (2.43) is better than 80.77% of its industry peers.
  • UCB has a Debt/Equity ratio of 0.29. This is a healthy value indicating a solid balance between debt and equity.
  • UCB has a better Debt to Equity ratio (0.29) than 67.31% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF 2.43
Altman-Z 5.66
ROIC/WACC1.46
WACC7.95%
UCB.BR Yearly LT Debt VS Equity VS FCFUCB.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.3 Liquidity

  • UCB has a Current Ratio of 1.35. This is a normal value and indicates that UCB is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of UCB (1.35) is comparable to the rest of the industry.
  • A Quick Ratio of 1.01 indicates that UCB should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.01, UCB perfoms like the industry average, outperforming 51.92% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.35
Quick Ratio 1.01
UCB.BR Yearly Current Assets VS Current LiabilitesUCB.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • UCB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 75.41%, which is quite impressive.
  • Measured over the past years, UCB shows a decrease in Earnings Per Share. The EPS has been decreasing by -0.86% on average per year.
  • The Revenue has grown by 25.56% in the past year. This is a very strong growth!
  • UCB shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.60% yearly.
EPS 1Y (TTM)75.41%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%68.9%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%24.94%

3.2 Future

  • UCB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.00% yearly.
  • Based on estimates for the next years, UCB will show a quite strong growth in Revenue. The Revenue will grow by 15.34% on average per year.
EPS Next Y60.25%
EPS Next 2Y43.7%
EPS Next 3Y38.91%
EPS Next 5Y30%
Revenue Next Year28.22%
Revenue Next 2Y20.45%
Revenue Next 3Y17.95%
Revenue Next 5Y15.34%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
UCB.BR Yearly Revenue VS EstimatesUCB.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B
UCB.BR Yearly EPS VS EstimatesUCB.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20 25

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 41.94, UCB can be considered very expensive at the moment.
  • UCB's Price/Earnings ratio is a bit more expensive when compared to the industry. UCB is more expensive than 63.46% of the companies in the same industry.
  • UCB's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.98.
  • The Price/Forward Earnings ratio is 26.18, which means the current valuation is very expensive for UCB.
  • UCB's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. UCB is more expensive than 61.54% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.01, UCB is valued at the same level.
Industry RankSector Rank
PE 41.94
Fwd PE 26.18
UCB.BR Price Earnings VS Forward Price EarningsUCB.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of UCB indicates a slightly more expensive valuation: UCB is more expensive than 63.46% of the companies listed in the same industry.
  • The rest of the industry has a similar Price/Free Cash Flow ratio as UCB.
Industry RankSector Rank
P/FCF 44.2
EV/EBITDA 21.64
UCB.BR Per share dataUCB.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • UCB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • UCB has a very decent profitability rating, which may justify a higher PE ratio.
  • UCB's earnings are expected to grow with 38.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.7
PEG (5Y)N/A
EPS Next 2Y43.7%
EPS Next 3Y38.91%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. Dividend

5.1 Amount

  • UCB has a yearly dividend return of 0.34%, which is pretty low.
  • UCB's Dividend Yield is slightly below the industry average, which is at 1.89.
  • Compared to an average S&P500 Dividend Yield of 1.81, UCB's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.34%

5.2 History

  • The dividend of UCB has a limited annual growth rate of 2.46%.
Dividend Growth(5Y)2.46%
Div Incr Years6
Div Non Decr Years6
UCB.BR Yearly Dividends per shareUCB.BR Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • 19.82% of the earnings are spent on dividend by UCB. This is a low number and sustainable payout ratio.
  • UCB's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP19.82%
EPS Next 2Y43.7%
EPS Next 3Y38.91%
UCB.BR Yearly Income VS Free CF VS DividendUCB.BR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B
UCB.BR Dividend Payout.UCB.BR Dividend Payout, showing the Payout Ratio.UCB.BR Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

UCB SA

EBR:UCB (2/25/2026, 11:39:59 AM)

269.25

-1.65 (-0.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A
Earnings (Next)02-26
Inst Owners41.62%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap52.37B
Revenue(TTM)6.85B
Net Income(TTM)1.33B
Analysts73.85
Price Target275.68 (2.39%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.34%
Yearly Dividend1.36
Dividend Growth(5Y)2.46%
DP19.82%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.49%
PT rev (3m)6.88%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)3.59%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)2.27%
Revenue NY rev (3m)4.16%
Valuation
Industry RankSector Rank
PE 41.94
Fwd PE 26.18
P/S 7.65
P/FCF 44.2
P/OCF 33.23
P/B 5.41
P/tB 48.18
EV/EBITDA 21.64
EPS(TTM)6.42
EY2.38%
EPS(NY)10.28
Fwd EY3.82%
FCF(TTM)6.09
FCFY2.26%
OCF(TTM)8.1
OCFY3.01%
SpS35.21
BVpS49.78
TBVpS5.59
PEG (NY)0.7
PEG (5Y)N/A
Graham Number84.8
Profitability
Industry RankSector Rank
ROA 7.75%
ROE 13.76%
ROCE 13.73%
ROIC 11.63%
ROICexc 13.71%
ROICexgc 58.2%
OM 26.58%
PM (TTM) 19.45%
GM 73.38%
FCFM 17.3%
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
ROICexc(3y)4.85%
ROICexc(5y)7.22%
ROICexgc(3y)28.31%
ROICexgc(5y)48.18%
ROCE(3y)5.15%
ROCE(5y)7.49%
ROICexgc growth 3Y-25.87%
ROICexgc growth 5Y-16.2%
ROICexc growth 3Y-19.14%
ROICexc growth 5Y-14.38%
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
F-Score9
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF 2.43
Debt/EBITDA 1.15
Cap/Depr 61.48%
Cap/Sales 5.71%
Interest Coverage 16.4
Cash Conversion 64.17%
Profit Quality 88.96%
Current Ratio 1.35
Quick Ratio 1.01
Altman-Z 5.66
F-Score9
WACC7.95%
ROIC/WACC1.46
Cap/Depr(3y)52.98%
Cap/Depr(5y)82.03%
Cap/Sales(3y)5.99%
Cap/Sales(5y)6.61%
Profit Quality(3y)131.69%
Profit Quality(5y)119.05%
High Growth Momentum
Growth
EPS 1Y (TTM)75.41%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%68.9%
EPS Next Y60.25%
EPS Next 2Y43.7%
EPS Next 3Y38.91%
EPS Next 5Y30%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%24.94%
Revenue Next Year28.22%
Revenue Next 2Y20.45%
Revenue Next 3Y17.95%
Revenue Next 5Y15.34%
EBIT growth 1Y258.97%
EBIT growth 3Y-13.71%
EBIT growth 5Y-5.23%
EBIT Next Year162.81%
EBIT Next 3Y59.8%
EBIT Next 5Y41.09%
FCF growth 1Y91.13%
FCF growth 3Y-4.61%
FCF growth 5Y9.37%
OCF growth 1Y61.64%
OCF growth 3Y-7.18%
OCF growth 5Y7.09%

UCB SA / UCB.BR FAQ

What is the fundamental rating for UCB stock?

ChartMill assigns a fundamental rating of 6 / 10 to UCB.BR.


Can you provide the valuation status for UCB SA?

ChartMill assigns a valuation rating of 4 / 10 to UCB SA (UCB.BR). This can be considered as Fairly Valued.


Can you provide the profitability details for UCB SA?

UCB SA (UCB.BR) has a profitability rating of 6 / 10.


What are the PE and PB ratios of UCB SA (UCB.BR) stock?

The Price/Earnings (PE) ratio for UCB SA (UCB.BR) is 41.94 and the Price/Book (PB) ratio is 5.41.


What is the earnings growth outlook for UCB SA?

The Earnings per Share (EPS) of UCB SA (UCB.BR) is expected to grow by 60.25% in the next year.